Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Tremfya (guselkumab) is a brand-name drug approved to treat ulcerative colitis (UC). This article covers topics such as side effects, dosage, and how Tremfya works. Tremfya is available as a ...

Johnson & Johnson (NYSE: JNJ) announced significant advancements in the treatment of moderately to severely active ulcerative colitis (UC) with its drug TREMFYA® (guselkumab). The Phase 3 ASTRO ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.

Living with ulcerative colitis doesn’t mean giving up the flavors you love. You can enjoy delicious meals without painful ...

(RTTNews) - Johnson & Johnson (JNJ) reported data from the Phase 3 ASTRO study of TREMFYA subcutaneous induction therapy in adults with moderately to severely active ulcerative colitis. The ...

US healthcare giant Johnson & Johnson has announced data from the Phase III ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous (SC) induction therapy in patients with moderately to severely active ulcerative colitis (UC). Study participants ...

Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA subcutaneous, SC, induction therapy in adults with moderately to ...